Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focused on PLK1 inhibition for cancer therapies, has announced it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT following market close.

Interested parties can access the webcast through the 'Investors' section of Cardiff Oncology's website. A replay of the call will be made available in the investor relations section afterward.

News Market Reaction

+1.06%

1 alert

+1.06% News Effect

On the day this news was published, CRDF gained 1.06%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

- Management will hold a conference call on Thursday, February 27 at 4:30 p.m. ET/1:30 p.m. PT -

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact: 
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com

FAQ

When will Cardiff Oncology (CRDF) report Q4 2024 earnings?

Cardiff Oncology will report its Q4 2024 earnings on Thursday, February 27, 2025, after market close.

What time is Cardiff Oncology's (CRDF) Q4 2024 earnings call?

The earnings conference call is scheduled for 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025.

How can investors access Cardiff Oncology's (CRDF) Q4 2024 earnings call?

Investors can access the live webcast through the 'Investors' section of Cardiff Oncology's website at https://investors.cardiffoncology.com/news-events/events.

Will there be a replay available for Cardiff Oncology's (CRDF) Q4 2024 earnings call?

Yes, a replay of the conference call will be available in the investor relations section of Cardiff Oncology's website after the call.